The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting a shift toward defensive positioning, US equities saw divergent performance as healthcare and telecom gains countered a sharp decline in the semiconductor space. Merck (MRK) shares climbed 3.23% following successful Phase 3 trial results for its immunology drug tulisokibart, while Verizon (VZ) rose 3.19% supported by a $1.8 billion debt repurchase plan. Conversely, Analog Devices (ADI) plummeted 9.23% amid a broader global sell-off in the semiconductor industry.
This sector rotation comes as investors weigh company-specific catalysts against macroeconomic headwinds. Per market data, Johnson & Johnson (JNJ) closed at $238.49 on June 23, 2026. The semiconductor slump was exacerbated by reports of SK Hynix slowing its HBM expansion, which triggered concerns over peak demand in the AI-linked chip sector, further pressured by hawkish sentiment regarding the Federal Reserve's interest rate trajectory.
Based on market levels at close on June 18, 2026, MRK stood at $113.87 and VZ at $45.37, while ADI was positioned at $434.46. Investors should watch for upcoming catalysts, including the impact of the Fed's recent decision to hold rates at 3.75% and the upcoming API Crude Oil Stock Change data, which could influence broader market volatility and sector-specific flows in the coming days.